Canaccord Genuity Reiterates a 'Buy' on AVEO Pharmaceuticals (AVEO); License Agreement Supports Platform Potential
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on AVEO Pharmaceuticals (NASDAQ: AVEO), PT $28.
Canaccord analyst, Dr. George Farmer, said, "We believe ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst, Dr. George Farmer, said, "We believe ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
